56 Citations (Scopus)

Abstract

Immunogenicity of antitumor necrosis factor-alpha (TNFα) agents has been proven to play a significant role in the variability of clinical responses among patients with chronic inflammatory diseases. However, its clinical impact on the outcome of patients with psoriasis and psoriatic arthritis receiving anti-TNFα treatment is not yet fully clear. Despite the high rates of efficacy of anti-TNFα agents in psoriasis, a substantial proportion of patients remain who experience a primary or secondary failure or significant side effects, which are potentially ascribable to immunogenicity.
Original languageEnglish
Pages (from-to)1673-1682
Number of pages10
JournalExpert Opinion on Biological Therapy
Volume13
DOIs
Publication statusPublished - 2013

Keywords

  • immunogenecity

Fingerprint

Dive into the research topics of 'Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?'. Together they form a unique fingerprint.

Cite this